2007
EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.Peer-Reviewed Original ResearchHigh EGFR expressionEGFR expressionRecurrent SCCHNTumor samplesCisplatin-based chemotherapySquamous cell carcinomaAssociation of responsePercentage of cellsHazard ratioProgressive diseaseCisplatin therapyPatient selectionCell carcinomaHigher eGFREGFR immunoreactivityInitial cohortCetuximabChemotherapyIndependent cohortFurther enrollmentPatientsSurvival analysisTumor resistanceDako kitSCCHN
1993
Differential Immunoreactivity of Epidermal Growth Factor Receptor in Benign, Dysplastic and Malignant Prostatic Tissues
Ibrahim G, Kerns B, MacDonald J, Ibrahim S, Kinney R, Humphrey P, Robertson C. Differential Immunoreactivity of Epidermal Growth Factor Receptor in Benign, Dysplastic and Malignant Prostatic Tissues. Journal Of Urology 1993, 149: 170-173. PMID: 7678041, DOI: 10.1016/s0022-5347(17)36032-9.Peer-Reviewed Original ResearchConceptsBenign prostatic hyperplasiaEGFR immunoreactivityBasal cell layerLuminal cellsBasal cellsBPH tissueFactor receptorProstatic specific antigenMalignant prostatic tissueAreas of dysplasiaCell layerRadical prostatectomy specimensCap tissueEpidermal growth factor receptorGrowth factor receptorEGFR contentProstatic hyperplasiaImmunohistochemical examinationProstatic carcinomaProstatic specimensProstatectomy specimensProstatic tissue
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply